NeuroScientific Biopharmaceuticals Ltd. has been informed by the Human Research Ethics Committee (HREC) it rejected the Company's planned Phase I Clinical Trial for EmtinBTM. In making its decision, HREC determined that at this stage the supporting documentation did not sufficiently address the risk-benefit profile to justify the conduct of the planned Phase I Clinical Trial. The HREC decision to not approve the Phase I Clinical Trial was unexpected and the Company is seeking clarification on the rationale for the decision to determine what steps can be taken to proceed with the Phase I Clinical Trial.
NeuroScientific Biopharmaceuticals Limited
Equities
NSB
AU0000012973
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.046 AUD | +2.22% | -6.12% | +4.55% |
1st Jan change | Capi. | |
---|---|---|
+4.55% | 4.3M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- NSB Stock
- News NeuroScientific Biopharmaceuticals Limited
- Neuroscientific Biopharmaceuticals Ltd. Announces HREC Decision to Not Approve Phase I Clinical Trial